



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalà
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugalsky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Teresa A. Medler
Jeffrey S. Weaver
Kenneth P. Patterson
Vincent L. Capuano
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes

Joseph S. Ostroff
Frank R. Cottingham
Christine M. Uhler
Rae Lynn P. Guest
George S. Bardmesser
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller
LuAnne M. DeSantis
Ann E. Summerfield
Aric W. Ledford
Helene C. Carlson
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Nicole D. Dretar

Ted J. Ebersole
Jyoti C. Iyer
Laura A. Vogel
Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Michelle K. Holoubek
Robert H. DeSelms
Simon J. Elliott

Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Michael G. Penn
Christopher J. Walsh

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

November 10, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8589

INTERNET ADDRESS:
LARRYB@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/764,604; Filed: January 27, 2004
For: **Compositions and Methods for Treating
Cancer Using IGSF9 and LIV-1**
Inventors: McLachlan *et al.*
Our Ref: 2159.0030001/LBB/PAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Twenty-six pages of Form PTO-1449;
3. Copies of documents AL1-AN1, AR1-AT1, AR2-AT2, AR3-AT3, AR4-AT4, AR5-AT5, AR6-AT6, AR7-AT7, AR8-AT8, AR9-AT9, AR10-AT10, AR11-AT11, AR12-AT12, AR13-AT13, AR14-AT14, AR15-AT15, AR16-AT16, AR17-AT17, AR18-AT18, AR19-AT19, AR20-AT20, AR21-AT21, AR22-AT22, AR23-AT23, AR24-AT24, AR25-AT25 and AR26-AT26 as listed on Form PTO-1449; and
4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
November 10, 2004
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lawrence B. Bugaisky
Attorney for Applicants
Registration No. 35,086

LBB/PAC:dbj
Enclosures

331431_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MC LACHLAN *et al.*

Appl. No.: 10/764,604

Filed: January 27, 2004

For: **Compositions and Methods for
Treating Cancer Using IGSF9
and LIV-1**

Confirmation No. 6570

Art Unit: 1614

Examiner *To Be Assigned*

Atty. Docket: 2159.0030001/LBB/PAC

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of U.S. patents and patent application publications, AA1-AK1, AA2-AK2, AA3-AK3, and AA4-AD4, cited on the attached Form PTO-1449 are not submitted in accordance with 1276 OG 55 because this application was filed after June 30, 2003. Copies of documents AL1-AN1, AR1-AT1, AR2-AT2, AR3-AT3, AR4-AT4, AR5-AT5, AR6-AT6, AR7-AT7, AR8-AT8, AR9-AT9, AR10-AT10, AR11-AT11, AR12-AT12, AR13-AT13, AR14-AT14, AR15-AT15, AR16-AT16, AR17-AT17, AR18-AT18, AR19-AT19, AR20-AT20, AR21-AT21, AR22-AT22, AR23-AT23, AR24-AT24, AR25-AT25 and AR26-AT26 are provided.

The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on

information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lawrence B. Bugaisky
Attorney for Applicants
Registration No. 35,086

Date: Nov 10, 2004
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

320635v1

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
2159.0030001/LBB/PACAPPLICATION NO.
10/764,604FIRST NAMED INVENTOR
McLachlan, *et al.*FILING DATE
January 27, 2004ART UNIT
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA1	4,676,980	06/30/1987	Segal <i>et al.</i>			09/23/1985
AB1	4,722,848	02/02/1988	Paoletti <i>et al.</i>			06/19/1984
AC1	4,816,567	03/28/1989	Cabilly <i>et al.</i>			04/08/1983
AD1	4,831,175	05/16/1989	Gansow <i>et al.</i>			09/05/1986
AE1	4,946,778	08/07/1990	Ladner <i>et al.</i>			01/19/1989
AF1	5,099,069	03/24/1992	Gansow <i>et al.</i>			12/16/1988
AG1	5,124,471	06/23/1992	Gansow <i>et al.</i>			03/26/1990
AH1	5,229,275	07/20/1993	Goroff			04/26/1990
AI1	5,246,692	09/21/1993	Gansow <i>et al.</i>			08/22/1991
AJ1	5,286,850	02/15/1994	Gansow <i>et al.</i>			05/11/1992
AK1	5,434,287	07/18/1995	Gansow <i>et al.</i>			11/04/1993

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL1	WO 93/11161	06/10/1993	WIPO			N/A
AM1	WO 94/13804	06/23/1994	WIPO			N/A
AN1	EP 0 368 684 B1	03/09/1994	Europe			N/A
AO						
AP						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Bierer, B. E., <i>et al.</i> , "Synergistic T Cell Activation Via The Physiological Ligands For CD2 And The T Cell Receptor," <i>J. Exp. Med.</i> 168: 1145-1156, Rockefeller University Press (1988)
AS	1	Bird, R. E., <i>et al.</i> , "Single-Chain Antigen-Binding Proteins," <i>Science</i> 242:423-426, American Association for the Advancement of Science (1988)
AT	1	Bowie, J. U., <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> 247:1306-1310, American Association for the Advancement of Science (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	5,460,785	10/24/1995	Rhodes <i>et al.</i>			01/03/1992
	AB2	5,545,806	08/13/1996	Lonberg <i>et al.</i>			12/16/1992
	AC2	5,545,807	08/13/1996	Surani <i>et al.</i>			08/05/1994
	AD2	5,567,610	10/22/1996	Borrebaeck <i>et al.</i>			10/17/1994
	AE2	5,569,825	10/29/1996	Lonberg <i>et al.</i>			12/17/1991
	AF2	5,585,089	12/17/1996	Queen <i>et al.</i>			06/07/1995
	AG2	5,591,669	01/07/1997	Krimpenfort <i>et al.</i>			05/30/1995
	AH2	5,648,267	07/15/1997	Reff			11/03/1993
	AI2	5,658,570	08/19/1997	Newman <i>et al.</i>			01/25/1995
	AJ2	5,693,761	12/02/1997	Queen <i>et al.</i>			06/07/1995
	AK2	5,693,762	12/2/1997	Queen <i>et al.</i>			06/07/1995

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>2</u>	Breathnach, R., <i>et al.</i> , "Ovalbumin gene: Evidence for a leader sequence in mRNA and DNA sequences at the exon-intron boundaries," <i>Proc. Natl. Acad. Sci. USA</i> 75:4853-4857, National Academy of Sciences (1978)
	AS	<u>2</u>	Brennan, M., <i>et al.</i> , "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G ₁ Fragments," <i>Science</i> 229:81-83, American Association for the Advancement of Science (1985)
	AT	<u>2</u>	Brüggemann, M., <i>et al.</i> , "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals," in <i>Generation of Antibodies by Cell and Gene Immobilization</i> , Terhorst, C., <i>et al.</i> , Karger AG, Basel, Switzerland, pp.33-40 (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3	5,693,780	12/2/1997	Newman <i>et al.</i>			06/07/1995
	AB3	5,733,779	03/31/1998	Reff			06/07/1995
	AC3	5,736,137	04/07/1998	Anderson <i>et al.</i>			11/03/1993
	AD3	5,756,096	05/26/1998	Newman <i>et al.</i>			06/07/1995
	AE3	5,811,524	09/22/1998	Brams <i>et al.</i>			06/07/1995
	AF3	5,843,439	12/01/1998	Anderson <i>et al.</i>			06/07/1995
	AG3	5,892,019	04/06/1999	Schlom <i>et al.</i>			09/01/1994
	AH3	5,939,598	08/17/1999	Kucherlapati <i>et al.</i>			07/30/1992
	AI3	5,969,108	10/19/1999	McCafferty <i>et al.</i>			01/08/1993
	AJ3	6,017,733	01/25/2000	Reff			01/26/1998
	AK3	6,075,181	06/13/2000	Kucherlapati <i>et al.</i>			06/07/1995

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Carrasquillo, J. A., <i>et al.</i> , "Improved Imaging of Metastatic Melanoma with High Dose 9.2.27 In-111 Monoclonal Antibody," <i>J. of Nucl. Med.</i> 26:P67, Society of Nuclear Medicine, Inc. (1985).
	AS	<u>3</u>	Carter, P., <i>et al.</i> , "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy," <i>Proc. Natl. Acad. Sci. USA</i> 89: 4285-4289, National Academy of Sciences (1992)
	AT	<u>3</u>	Chabner, <i>et al.</i> , "Antineoplastic Agents," in <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , 9 th ed., Wonsiewicz, M. J., and McCurdy, P., eds., McGraw-Hill, New York, NY, pp. 1233-1287 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA4	6,159,730	12/12/2000	Reff			03/30/1999
	AB4	6,193,980	02/27/2001	Efstathiou <i>et al.</i>			09/17/1997
	AC4	6,399,061	06/04/2002	Anderson <i>et al.</i>			06/07/1995
	AD4	6,682,734	01/27/2004	Anderson <i>et al.</i>			06/07/1995
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	Chothia, C., and Lesk, A. M., "Canonical Structures for the Hypervariable Regions of Immunoglobulins," <i>J. Mol. Biol.</i> 196:901-917, Academic Press Ltd. (1987)
	AS	<u>4</u>	Clackson, T., <i>et al.</i> , "Making antibody fragments using phage display libraries," <i>Nature</i> 352:624-628, Macmillan Magazines Ltd. (1991)
	AT	<u>4</u>	Cunningham, B. C., and Wells, J. A., "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis," <i>Science</i> 244:1081-1085, American Association for the Advancement of Science (1989)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

[illegible]

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>5</u>	De Vos, A. M., <i>et al.</i> , "Human Growth and Extracellular Domain of Its Receptor: Crystal Structure of the Complex," <i>Science</i> 255:306-312, American Association for the Advancement of Science (1992)
	AS	<u>5</u>	Doudney, K., <i>et al.</i> , "Cloning and Characterization of <i>Igsf9</i> in Mouse and Human: A New Member of the Immunoglobulin Superfamily Expressed in the Developing Nervous System," <i>Genomics</i> 79:663-670, Elsevier Science (May 2002)
	AT	<u>5</u>	Fields, S., and Song, O., " A novel genetic system to detect protein-protein interactions," <i>Nature</i> 340: 245-246, Macmillan Magazines Ltd. (1989)

DATE CONSIDERED

317165 1.DOC

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>6</u>	Freedman, A. S., and Nadler, L. M., "Malignant Lymphomas," in <i>Harrison's Principles of Internal Medicine</i> , 13 th ed., Isselbacher, K. J., <i>et al.</i> , eds., McGraw Hill, Inc., New York, NY (1994)
	AS	<u>6</u>	Freshney, R. I., "Quantitation and Experimental Design," in <i>Culture of Animal Cells</i> , Alan R. Liss, Inc., New York, NY, pp. 227-296 (1987)
	AT	<u>6</u>	Gautier, C., <i>et al.</i> , "α-DNA IV: α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding," <i>Nucleic Acids Research</i> 15:6625-6641, IRL Press Ltd. (1987)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2159.0030001/LBB/PACAPPLICATION NO.
10/764,604FIRST NAMED INVENTOR
McLachlan, *et al.*FILING DATE
January 27, 2004ART UNIT
1614**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>I</u>	Gentz, R., <i>et al.</i> , "Bioassay for trans-activation using purified human immunodeficiency virus <i>tat</i> -encoded protein: Trans-activation requires mRNA synthesis," <i>Proc. Natl. Acad. Sci. USA</i> 86: 821-824, National Academy of Sciences (1989)
	AS	<u>I</u>	Giovanella, B. C., <i>et al.</i> , "Heterotransplantation of Human Malignant Tumors in "Nude" Thymusless Mice. II. Malignant Tumors Induced by Injection of Cell Cultures Derived From Human Solid Tumors," <i>Journal of the National Cancer Institute</i> 52:921-930, U.S. Dept. of Health, Education, and Welfare (1974)
	AT	<u>I</u>	Goding, J. W., "Production of Monoclonal Antibodies," in <i>Monoclonal Antibodies: Principles and Practice</i> , 2 nd ed., Academic Press Inc., London, pp. 59-103 (1986).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2159.0030001/LBB/PACAPPLICATION NO.
10/764,604FIRST NAMED INVENTOR
McLachlan, *et al.*FILING DATE
January 27, 2004ART UNIT
1614**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>8</u>	Griffiths, A. D., <i>et al.</i> , "Human anti-self antibodies with high specificity from phage display libraries," <i>EMBO J.</i> 12:725-734, Oxford University Press (1993).
	AS	<u>8</u>	Holliger, P., <i>et al.</i> , ""Diabodies": Small bivalent and bispecific antibody fragments," <i>Proc. Natl. Acad. Sci. USA</i> 90:6444-6448, National Academy of Sciences (1993)
	AT	<u>8</u>	Huse, W. D., <i>et al.</i> , "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>Science</i> 246:1275-1281, American Association for the Advancement of Science (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2159.0030001/LBB/PACAPPLICATION NO.
10/764,604FIRST NAMED INVENTOR
McLachlan, *et al.*FILING DATE
January 27, 2004ART UNIT
1614**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>9</u>	Huston, J. S., <i>et al.</i> , "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 85:5879-5883, National Academy of Sciences (1988)
	AS	<u>9</u>	Inoue, H., <i>et al.</i> , "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H," <i>Febs Letters</i> 215:327-330, Elsevier Science Publishers B.V. (1987)
	AT	<u>9</u>	Inoue, H., <i>et al.</i> , "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides, " <i>Nucleic Acids Research</i> 15:6131-6148, IRL Press Ltd. (1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[illegible][illegible]

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>10</u>	Jakobovits, A., <i>et al.</i> , "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production," <i>Proc. Natl. Acad. Sci. USA</i> 90:2551-2555, National Academy of Sciences (1993)
	AS	<u>10</u>	Jakobovits, A., <i>et al.</i> , "Germ-line transmission and expression of a human-derived yeast artificial chromosome," <i>Nature</i> 362:255-258, Macmillan Magazines Ltd. (1993)
	AT	<u>10</u>	Johnson, K. S., and Chiswell, D.J., "Human antibody engineering," <i>Curr. Opin. Struct. Biol.</i> 3:564-571, Current Biology Ltd. (1993)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[illegible][illegible]

	AR	<u>11</u>	Jones, E. W., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> ," <i>Genetics</i> 85:23-33, Genetics Society of America, Inc. (1977).
	AS	<u>11</u>	Jones, P. T., <i>et al.</i> , "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> 321:522-525, Macmillan Journals Ltd. (1986)
	AT	<u>11</u>	Kingsman, A. J., <i>et al.</i> , "Replication in <i>Saccharomyces cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast <i>trpI</i> Region," <i>Gene</i> 7:141-152, Elsevier/North-Holland Biomedical Press (1979)

DATE CONSIDERED

317165_1.DOC

[illegible][illegible]

	AR	<u>12</u>	Köhler, G., and Milstein, C., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> 256:495-497, Macmillan Journals Ltd. (1975)
	AS	<u>12</u>	Kyte, J., and Doolittle, R. F., "A Simple Method for Displaying the Hydropathic Character of a Protein," <i>J. Mol. Biol.</i> 157:105-132, Academic Press Ltd. (1982)
	AT	<u>12</u>	Li, Y., and Zhu, C., "A modified Boyden chamber assay for tumor cell transendothelial migration <i>in vitro</i> ," <i>Clinical & Experimental Metastasis</i> 17:423-429, Kluwer Academic Publishers (1999)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2159.0030001/LBB/PACAPPLICATION NO.
10/764,604FIRST NAMED INVENTOR
McLachlan, *et al.*FILING DATE
January 27, 2004ART UNIT
1614**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>13</u>	Marks, J. D., <i>et al.</i> , "By-passing Immunization: Human Antibodies from V-gene Libraries Displayed on Phage," <i>J. Mol. Biol.</i> 222:581-597, Academic Press Ltd. (1991)
	AS	<u>13</u>	Marks, J. D., <i>et al.</i> , "By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technology</i> 10:779-783, Nature Publishing Co. (1992)
	AT	<u>13</u>	McCafferty, J., <i>et al.</i> , "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> 348:552-554, Macmillan Magazines Ltd. (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
2159.0030001/LBB/PAC
FIRST NAMED INVENTOR
McLachlan, *et al.*
FILING DATE
January 27, 2004

APPLICATION NO.
10/764,604

ART UNIT
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
						Yes
						No
						Yes
						No
						Yes
						No
						Yes
						No
						Yes
						No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>14</u>	Milstein, C., and Cuello, A. C., "Hybrid hybridomas and their use in immunohistochemistry," <i>Nature</i> 305:537-540, Macmillan Journals Ltd. (1983)
AS	<u>14</u>	Mobley, J. L., and Shimizu, Y., "Measurement of Cellular Adhesion Under Static Conditions," in <i>Current Protocols in Immunology</i> , Coligan, J. E., <i>et al.</i> , eds., John Wiley & Sons, Inc., New York, NY, Ch. 7.28 (1994).
AT	<u>14</u>	Morrison, S. L., <i>et al.</i> , "Chimeric human antibody molecules; Mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855, National Academy of Sciences (1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>15</u>	Morrison, S. L., and Oi, V., "Genetically Engineered Antibody Molecules," in <i>Advances in Immunology</i> , Vol. 44, Dixon, F. J., ed., Academic Press, Inc., San Diego, CA, pp.65-92 (1989)
	AS	<u>15</u>	Haynic, T.P., <i>et al.</i> , "The Effect of Radionuclide Dose on Imaging With Indium-111-Labeled Anti P-97 Monoclonal Antibody," <i>J. of Nuclear Medicine</i> 26:328-329, Society of Nuclear Medicine, Inc. (1985)
	AT	<u>15</u>	Newman, R., <i>et al.</i> , ""Primatization" of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4," <i>Bio/Technology</i> 10:1455-1460, Nature Publishing Co. (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>16</u>	Old, L. J., "Cancer Immunology: The Search for Specificity--G. H. A. Clowes Memorial Lecture," <i>Cancer Res.</i> 41:361-375, American Association for Cancer Research (1981)
	AS	<u>16</u>	Padlan, E. A., "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties," <i>Molecular Immunology</i> 28:489-498, Pergamon Press (1991)
	AT	<u>16</u>	Padlan, E. A., "Anatomy of the Antibody Molecule," <i>Mol. Immunol.</i> 31:169-217, Pergamon Press (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
2159.0030001/LBB/PACAPPLICATION NO.
10/764,604FIRST NAMED INVENTOR
McLachlan, *et al.*FILING DATE
January 27, 2004ART UNIT
1614**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>17</u>	Parker, C. W., "Radiolabeling of Proteins," in <i>Methods in Enzymology</i> , Vol. 182: <i>Guide to Protein Purification</i> , Deutscher, M. P., ed., Academic Press, Inc. San Diego, CA, pp. 721-737 (1990)
	AS	<u>17</u>	Pietersz, G. A., <i>et al.</i> , "The use of monoclonal antibody conjugates for diagnosis and treatment of cancer," <i>Immunology and Cell Biology</i> 65:111-125, University of Adelaide (1987)
	AT	<u>17</u>	Pilkington, G. J., <i>et al.</i> , " <i>In Vitro</i> and <i>in Vivo</i> Models for the Study of Brain Tumour Invasion," <i>Anticancer Research</i> 17:4107-4110, J.G. Delinassios, <i>Anticancer Research</i> (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>18</u>	Presta, L.G., "Antibody engineering," <i>Current Opinion in Structural Biology</i> 2:593-596, Current Biology Ltd. (1992)
	AS	<u>18</u>	Presta, L., <i>et al.</i> , "Humanization of an Antibody Directed Against IgE," <i>J. Immunol.</i> 151:2623-2632, American Association of Immunologists (1993)
	AT	<u>18</u>	Reisfeld, R. A., and Cheresh, D. A., "Human Tumor Antigens," in <i>Advances in Immunology</i> , Vol. 40, Dixon, F. J., ed., Academic Press, Inc., Orlando, FL, pp. 323-377 (1987)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>19</u>	Ribatti, D., <i>et al.</i> , "The chick embryo chorioallantoic membrane as a model for <i>in vivo</i> research on angiogenesis," <i>Int. J. Dev. Biol.</i> 40: 1189-1197, UBC Press (1996)
	AS	<u>19</u>	Riechmann, L., <i>et al.</i> , "Reshaping human antibodies for therapy," <i>Nature</i> 332:323-327, Macmillan Magazines Ltd. (1988)
	AT	<u>19</u>	Rodriguez, R. L., and Denhardt, D. T., eds., "Introduction of Vector into Host Cells," in <i>Vectors: A Survey of Molecular Cloning Vectors and Their Uses</i> , Butterworth Publishers, Stoneham, MA, pp. 471-473 (1988)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[illegible]

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>20</u>	Rosenberg, S. A ., ed., (Table of Contents), <i>Serologic Analysis of Human Cancer Antigens</i> , Academic Press, Inc., New York, NY, pp. v-x (1980)
	AS	<u>20</u>	Rosenstein, Y. <i>et al.</i> , "Direct Evidence for Binding of CD8 to HLA Class I Antigens," <i>J. Exp. Med.</i> 169:149-160, Rockefeller University Press (1989)
	AT	<u>20</u>	Shalaby, M. R., <i>et al.</i> , "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the <i>HER2</i> Protooncogene," <i>J. Exp. Med.</i> 175:217-225, Rockefeller University Press (1992)

[illegible][illegible]

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>21</u>	Sims, M. J., <i>et al.</i> , "A Humanized CD18 Antibody Can Block Function without Cell Destruction," <i>J. Immunol.</i> 151:2296-2308, American Association of Immunologists (1993)
	AS	<u>21</u>	Smith, D. B., and Johnson, K.S., "Single-step purification of polypeptides expressed in <i>Escherichia coli</i> as fusions with glutathione S-transferase," <i>Gene</i> 67:31-40, Elsevier Science Publishers B.V. (1988)
	AT	<u>21</u>	Smith, L. J., <i>et al.</i> , "Human Interleukin 4: The Solution Structure of a Four-helix Bundle Protein," <i>J. Mol. Biol.</i> 224:899-904, Academic Press Ltd. (1992)

DATE CONSIDERED

317165_1.DOC

[illegible][illegible]

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>22</u>	Smith, T. F., and Waterman, M. S., "Comparison of Biosequences," in <i>Advances in Applied Mathematics</i> , Vol. 2, Rota, G., ed., Academic Press, Inc., New York, NY, pp. 482-489 (1981)
	AS	<u>22</u>	Stein, C .A., and Cohen, J. S., "Phosphorothioate Oligodeoxynucleotide Analogues," in <i>Oligodeoxynucleotide: Antisense Inhibitors of Gene Expression</i> , Cohen, J. S., ed., CRC Press, Inc., Boca Raton, FL, pp. 97-117 (1989)
	AT	<u>22</u>	Stinchcomb, D.T., <i>et al.</i> , "Isolation and characterisation of a yeast chromosomal replicator," <i>Nature</i> 282:39-43, Macmillan Journals Ltd. (1979)

EXAMINER	DATE CONSIDERED
----------	-----------------

SKGF Rev. 12/03/03

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>23</u>	Stitt, T. N., <i>et al.</i> , "The Anticoagulation Factor Protein S and Its Relative, Gas6, Are Ligands for the Tyro 3/Axl Family of Receptor Tyrosine Kinases," <i>Cell</i> 80:661-670, Cell Press (1995)
	AS	<u>23</u>	Stoltenborg, J. K., <i>et al.</i> , "A fluorescent cellular adhesion assay using insect cell produced human VCAM1," <i>J. Immunol. Meth.</i> 175:59-68, Elsevier Science B.V. (1994)
	AT	<u>23</u>	Stover, C. K., <i>et al.</i> , "New use of BCG for recombinant vaccines," <i>Nature</i> 351:456-460, Macmillan Magazines Ltd. (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2159.0030001/LBB/PAC	APPLICATION NO. 10/764,604
	FIRST NAMED INVENTOR McLachlan, <i>et al.</i>	
	FILING DATE January 27, 2004	ART UNIT 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>24</u>	Suresh, M. R., <i>et al.</i> , "Bispecific Monoclonal Antibodies from Hybrid Hybridomas," in <i>Methods in Enzymology, Vol. 121: Immunochemical Techniques</i> , Langone, J. L., and Van Vunakis, H., eds., Academic Press, Inc., Orlando, FL, pp. 210-229 (1986)
	AS	<u>24</u>	Takai, Y., <i>et al.</i> , "Direct evidence for a receptor-ligand interaction between the T-cell surface antigen CD2 and lymphocyte-function-associated antigen 3," <i>Proc. Natl. Acad. Sci. USA</i> 84:6864-6868, National Academy of Sciences (1987)
	AT	<u>24</u>	Taylor, K. M., "LIV-1 Breast Cancer Protein Belongs to New Family of Histidine-Rich Membrane Proteins with Potential to Control Intracellular Zn ²⁺ Homeostasis," <i>IUBMB Life</i> 49:249-253, Taylor & Francis, Inc. (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
2159.0030001/LBB/PACAPPLICATION NO.
10/764,604FIRST NAMED INVENTOR
McLachlan, *et al.*FILING DATE
January 27, 2004ART UNIT
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>25</u>	Verhoeven, M., <i>et al.</i> , "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> 239:1534-1536, American Association for the Advancement of Science (1988)
	AS	<u>25</u>	Tschumper, G., and Carbon, J., "Sequence of a yeast DNA fragment containing a chromosomal replicator and the <i>TRP1</i> gene," <i>Gene</i> 10:157-166, Elsevier/North-Holland Biomedical Press (1980)
	AT	<u>25</u>	Tutt, A., <i>et al.</i> , "Trispecific F(ab') ₃ Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells," <i>J. Immunol.</i> 147:60-69, American Association of Immunologists, (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[illegible][illegible]

AR	<u>26</u>	Urlaub, G., <i>et al.</i> , "Effect of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions," <i>Somatic Cell and Molecular Genetics</i> 12:555-566, Plenum Publishing Corp. (1986)
AS	<u>26</u>	Ward, E. S., <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> 341:544-546, Macmillan Magazines Ltd. (1989)
AT	<u>26</u>	Wilson, I. A., <i>et al.</i> , "The Structure of an Antigenic Determinant in a Protein," <i>Cell</i> 37:767-778, Cell Press (1984)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.